[1]张 萍,任世云,张 雷.乳腺癌患者血清脂质运载蛋白-2 和基质金属蛋白酶-9的表达及临床意义[J].现代检验医学杂志,2015,30(01):72-74.[doi:10.3969/j.issn.1671-7414.2015.01.019]
　ZHANG Ping,REN Shi-yun,ZHANG Lei.Expression and Clinical Significance of Serum LCN-2 and MMP-9 in Patients with Breast Cancer[J].Journal of Modern Laboratory Medicine,2015,30(01):72-74.[doi:10.3969/j.issn.1671-7414.2015.01.019]
点击复制

乳腺癌患者血清脂质运载蛋白-2 和基质金属蛋白酶-9的表达及临床意义()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第30卷
期数:
2015年01期
页码:
72-74
栏目:
论著
出版日期:
2015-01-30

文章信息/Info

Title:
Expression and Clinical Significance of Serum LCN-2 and MMP-9 in Patients with Breast Cancer
文章编号:
1671-7414(2015)01-072-03
作者:
张 萍; 任世云; 张 雷
长白山保护开发区中心医院检验科,吉林长白山 133613
Author(s):
ZHANG Ping; REN Shi-yun; ZHANG Lei
Department of Clinical Laboratory, Center Hospital of Changbaishang Protection Zones,Jilin Changbaishang 133613,China
关键词:
乳腺癌;  脂质运载蛋白-2;  基质金属蛋白酶-9;  淋巴结转移
分类号:
R737.9; R730.43
DOI:
10.3969/j.issn.1671-7414.2015.01.019
文献标志码:
A
摘要:
目的 探讨血清脂质运载蛋白-2(LCN-2)和基质金属蛋白酶-9(MMP-9)在乳腺癌中的表达及临床意义。方法 应用酶联免疫吸附法(ELISA)检测96例乳腺癌患者血清LCN-2和MMP-9的表达水平,并与42例乳腺良性病变患者和27例健康对照者比较,分析其与肿瘤大小、TNM 分期、分化程度、淋巴结转移以及ER,PR表达的关系。结果 乳腺癌患者血清LCN-2表达量为89.76±28.38 ng/ml,明显高于乳腺良性病变组的56.44±21.15 ng/ml和健康对照组的44.32±16.84 ng/ml,差异均具有统计学意义(P<0.05),而乳腺良性病变组与健康对照组无明显差异(P>0.05)。乳腺癌患者血清MMP-9的表达量为96.34±23.26ng/ml,明显高于乳腺良性病变组的28.16±11.57 ng/ml和健康对照组的23.54±13.61 ng/ml,差异均具有统计学意义(P<0.05),而乳腺良性病变组与健康对照组无明显差异(P>0.05); 相关分析显示,乳腺癌患者血清LCN-2和MMP-9水平之间呈正相关(r= 0.513 5,P<0.05)。乳腺癌患者血清LCN-2和MMP-9的表达水平与肿瘤大小、淋巴结转移情况、ER和PR表达、TNM分期明显相关(P<0.05); 但与肿瘤分化程度无明显相关性(P>0.05)。结论 LCN-2和MMP-9可能在乳腺癌的发生、发展中起着重要作用,两者联合检测对于乳腺癌的辅助诊断、疗效监测及预后判断具有一定的临床意义。
Abstract:
Objective To evaluate the expression and its clinical significance of serum LCN-2 and MMP-9 in human breast cancer.Methods 96 patients with breast cancer,42 patients with benign breast diseases and 27 healthy controls were recruited in this study.The LCN-2 and MMP-9 levels were measured by ELISA in the serum of 96 patients with breastcancer,42 patients with benign breast disease,and 27 health controls.Results The level of serum LCN-2 in the breast cancer group(89.76±28.38 ng/ml)was significantly higher than those in benign breast diseases(56.44±21.15 ng/ml)and healthy controls(44.32±16.84 ng/ml)(P<0.05).The level of serum MMP-9 in the breast cancer group(96.34±23.26 ng/ml)was significantly higher than those in benign breast diseases(28.16±11.57 ng/ml)and healthy controls(23.54±13.61 ng/ml)(P<0.05).No obvious difference in the levels of serum LCN-2 and MMP-9 was observed between benign breast disease and healthy controls(P>0.05).Correlation analysis showed that a positive correlation was found between the levels of serum LCN-2 and MMP-9in breast cancer patients(r=0.513 5,P<0.05).The levels of serum LCN-2 and MMP-9 were significantly associated with tumor size,lymph node metastasis,the expression of ER and PR,TNM stage,but were not associated with tumor differentiation(P>0.05).The correlation analysis showed that the LCN-2 level was positive correlated with the MMP-9 level(P<0.05).Conclusion LCN-2 and MMP-9 could play a role in the tumorigenesis and development of breast cancer.Measuring of serum LCN-2 and MMP-9 may be a useful tool for diagnosis,effect monitoring and prognosis in breast cancer.

参考文献/References:

[1] Scully OJ,Bay BH,Yip G,et al.Breast cancer metastasis[J].Cancer Genomics Proteomics,2012,9(5):311-320.
[2] Kjeldsen L,Johnsen AH,Sengelov H,et al.Isolation and primary structure of NGAL,a novel protein associated with human neutrophil gelatinase[J].J Biol Chem,1993,268(14):10425-10432.
[3] Yang J, Bielenberg DR, Rodig SJ,et al.Lipocalin 2 promotes breast cancer progression[J].Proc Natl Acad Sci USA,2009,106(10):3913-3918.
[4] Zheng L,Zhang YM,Zhan YZ,et al.Momordica co-chinchinensis seed extracts suppress migration and invasion of human breast cancer ZR-75-30 cells viadown-regulating MMP-2 and MMP-9[J].Asian Pac J Cancer Prev,2014,15(3):1105-1110.
[5] Bauer M,Eickhoff JC,Gould MN,et al.Neutrophil gelatinaseassociated lipocalin(NGAL)is a predictor of poor prognosis in human primary breast cancer[J].Breast Cancer Res Treat,2008,108(3):389-397.
[6] Berger T,Cheung CC,Elia AJ,et al.Disruption of the lcn 2 gene in micesuppresses primary mammary tumor formation but does not decrease lung metastasis[J].Proc Natl Acad Sci USA,2010,107(7):2995-3000.
[7] Sung H,Choi JY,Lee SA,et al.The association between the preoperativeserum levels of lipocalin-2 and matrix metalloproteinase-9(MMP-9)and prognosis of breast cancer[J].BMC Cancer,2012(12):193.
[8] Zucker S,Lysik RM,DiMassimo BI,et al.Plasma assay of gelatinase B: tissue inhibitor of metalloproteinase complexes in cancer[J].Cancer,1995,76(4):700-708.
[9] Talvensaari-Mattila A,Turpeenniemi-Hujanen T.Pr-eoperative serum MMP-9 immunoreactive protein is a prognostic indicator for relapse-free survivalin breast carcinoma[J].Cancer Lett,2005,217(2):237-242.
[10] Susskind H,Hymowitz MH,Lau YH,et al.Increased plasma levelsof matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in lung and breast cancer are altered during chest radiotherapy[J].Int J Radiat Oncol Biol Phys,2003,56(4):1161-1169.
[11] Yan L,Borregaard N,Kjeldsen L,et al.The high molecular weight urinary matrix metalloproteinase(MMP)activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin(NGAL).Modulation of MMP-9 activity by NGAL[J].J Biol Chem,2001,276(40):37258-37265.
[12] Nuntagowat C, Leelawat K, Tohtong R.NGAL knockdown by siRNA in humancholangiocarcinoma cells suppressed invasion by reducing NGAL/MMP-9 complex formation[J].Clinical Experimental Metastasis,2010,27(5):295-305.
[13] Perrin C,Patard JJ,Jouan F,et al.The neutrophil gelatinase-associated lipocalin,or LCN 2,marker of aggressiveness in clear cell renal cell carcinoma[J].Prog Urol,2011,21(12):851-858.
[14] Fernández CA,Yan L,Louis G,et al.The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients[J].Clin Cancer Res,2005,11(15):5390-5395.

相似文献/References:

[1]党小军,张华,王欣.人附睾蛋白4(HE4)在乳腺癌诊断中的价值[J].现代检验医学杂志,2015,30(06):84.[doi:10.3969/j.issn.1671-7414.2015.06.024]
　DANG Xiao-jun,ZHANG Hua,WANG Xin.Value of Human Epididymis Protein 4(HE4) in Diagnosis of Breast Cancer[J].Journal of Modern Laboratory Medicine,2015,30(01):84.[doi:10.3969/j.issn.1671-7414.2015.06.024]
[2]乔雪峰a,黄志平b,张 宁c,等.IL-18基因启动子区-137G/C,-607G/T 2个位点基因多态性与女性乳腺癌易感性Meta分析[J].现代检验医学杂志,2016,31(04):65.[doi:10.3969/j.issn.16717-414.2016.04.017]
　QIAO Xue-fenga,HUANG Zhi-pingb,ZHANG Ningc,et al.Association Analysis of IL-18 Gene Promoter Region -137G/C,-607G/T Polymorphisms and Susceptibility to Sporadic Breast Cancer:Meta-Analysis[J].Journal of Modern Laboratory Medicine,2016,31(01):65.[doi:10.3969/j.issn.16717-414.2016.04.017]
[3]刘延梅,马少君,张月浪,等.人类表皮生长因子受体2在乳腺癌表达与临床的相关病理特征分析[J].现代检验医学杂志,2016,31(05):91.[doi:10.3969/j.issn.1671-7414.2016.05.024]
　LIU Yan-mei,MA Shao-jun,ZHANG Yue-lang,et al.Expression of Human Epidermal Growth Factor Receptor 2 and Correlation with Clinical Pathological Features in Breast Cancer[J].Journal of Modern Laboratory Medicine,2016,31(01):91.[doi:10.3969/j.issn.1671-7414.2016.05.024]
[4]陈雨欣,谭婷婷,宁明哲.乳腺癌患者血清中白介素35(IL-35)的表达及其临床意义[J].现代检验医学杂志,2017,32(02):92.[doi:10.3969/j.issn.1671-7414.2017.02.025]
　CHEN Yu-xin,TAN Ting-ting,NING Ming-zhe.Serological Interleukin-35 Level in Patients with Breast Cancer and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2017,32(01):92.[doi:10.3969/j.issn.1671-7414.2017.02.025]
[5]唐努尔·艾尔肯,阿孜古·祖农.盐酸罗哌卡因对人乳腺癌细胞运动作用的研究[J].现代检验医学杂志,2017,32(03):128.[doi:10.3969/j.issn.1671-7414.2017.03.035]
　TANGNUER·Aierken,AZIGU·Zunong.Study on Effect of Ropivacaine on Migration of Breast Cancer Cell s[J].Journal of Modern Laboratory Medicine,2017,32(01):128.[doi:10.3969/j.issn.1671-7414.2017.03.035]
[6]靳庆娥,苏建荣.北京地区汉族女性人群SYK基因启动子区-803A>Trs290987单核苷酸多态性与乳腺癌易感性分析[J].现代检验医学杂志,2018,33(02):5.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　JIN Qing-e,SU Jian-rong.Associations of SYK Promoter-803A >T(rs290987)Single Nucleotide Polymorphisms with Susceptibility to Breast Cancer of Han Female Population in Beijing Area[J].Journal of Modern Laboratory Medicine,2018,33(01):5.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[7]高 华a,李玉柱b,韩龙才c,等.Logistic回归和ROC工作曲线评价联合检测血清CA153,TPS,CYFRA21-1在乳腺癌诊断中的临床价值[J].现代检验医学杂志,2018,33(03):60.[doi:10.3969/j.issn.1671-7414.2018.03.016]
　GAO Huaa,LI Yu-zhub,HAN Long-caic,et al.Clinical Value of Logistic Regression and ROC Work Curve Evaluating Serum CA153,TPS and Cyfra21-1 for Diagnosis of Breast Cancer[J].Journal of Modern Laboratory Medicine,2018,33(01):60.[doi:10.3969/j.issn.1671-7414.2018.03.016]
[8]李 娜a,赵晓娟b,苏晓明a.乳腺组织中SMG-1mRNA和SOX4mRNA检测在乳腺癌监测中的应用[J].现代检验医学杂志,2019,34(02):35.[doi:10.3969/j.issn.1671-7414.2019.02.010]
　LI Naa,ZHAO Xiao-juanb,SU Xiao-minga.Application of Detection of SMG-1mRNA and SOX4mRNAin Breast Tissue in Surveillance for Breast Cancer[J].Journal of Modern Laboratory Medicine,2019,34(01):35.[doi:10.3969/j.issn.1671-7414.2019.02.010]
[9]王 碧,吉茂礼.乳腺癌组织长链非编码RNA UCA1和BCAR4表达与辅助化疗效果的相关性研究[J].现代检验医学杂志,2019,34(05):77.[doi:10.3969/j.issn.1671-7414.2019.05.019]
　WANG Bi,JI Mao-li.Correlational Research on the Expressionof Long-Chain Non-Coding RNA UCA1 and BCAR4in Breast Cancer Tissues for the Effect of Adjuvant Chemotherapy[J].Journal of Modern Laboratory Medicine,2019,34(01):77.[doi:10.3969/j.issn.1671-7414.2019.05.019]
[10]王承霞,朱玉蓉.乳腺癌患者血清中 tRF-32-Q99P9P9NH57SJ的表达及临床意义[J].现代检验医学杂志,2019,34(06):16.[doi:10.3969 ／ j.issn.1671-7414.2019.06.004]
　WANG Cheng-xia,ZHU Yu-rong.Expression and Clinical Significance of tRF-32-Q99P9P9NH57SJ in Serum of Patients with Breast Cancer[J].Journal of Modern Laboratory Medicine,2019,34(01):16.[doi:10.3969 ／ j.issn.1671-7414.2019.06.004]

备注/Memo

备注/Memo:

作者简介:张 萍(1974-),女,大专,主管检验师,研究方向:临床检验及肿瘤研究,E-mail:zhping1974@yeah.net。
更新日期/Last Update: 2015-01-30